Cost effectiveness analysis based on reported data (primary analysis), and sensitivity analysis based on a worst case scenario considering the maximum predicted number of incorrect diagnoses
| Primary analysis | Sensitivity analysis* | |
|---|---|---|
| Values are mean (95% confidence interval or uncertainty interval) per 100 000 births. | ||
| *Excludes 33 cases of possible incorrect diagnoses, including five predicted cases of haemorrhagic stroke/arteriovenous malformation, and an estimated 28 cases with normal prothrombin values in whom prior administration of vitamin K could not be established with certainty (see text). | ||
| †Currency conversion rates (26 March 2004): US$1.00 = £0.55, €0.82. | ||
| Incidence | 116 (102 to 132) | 100 (87 to 115) |
| Deaths | 11 (7 to 14) | 9 (6 to 13) |
| Years of life lost | 340 (220 to 470) | 290 (200 to 410) |
| Life long disability | 53 (41 to 66) | 45 (35 to 57) |
| Years lived with disability | 820 (630 to 1000) | 700 (540 to 890) |
| Cost of prophylaxis (US$)† | 100000 (76000 to 124000) | 100000 (76000 to 124000) |
| Cost effectiveness ratio (US$)† | 87 (60 to 120) | 100 (69 to 140) |